ID   CSK21_HUMAN             Reviewed;         391 AA.
AC   P68400; B4DYS6; D3DVV8; P19138; P20426; Q14013; Q5U065;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 1.
DT   12-OCT-2022, entry version 195.
DE   RecName: Full=Casein kinase II subunit alpha;
DE            Short=CK II alpha;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:30699359};
GN   Name=CSNK2A1; Synonyms=CK2A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2752008; DOI=10.1021/bi00435a066;
RA   Meisner H., Heller-Harrison R., Buxton J., Czech M.P.;
RT   "Molecular cloning of the human casein kinase II alpha subunit.";
RL   Biochemistry 28:4072-4076(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2174700; DOI=10.1021/bi00488a034;
RA   Lozeman F.J., Litchfield D.W., Piening C., Takio K., Walsh K.A.,
RA   Krebs E.G.;
RT   "Isolation and characterization of human cDNA clones encoding the alpha and
RT   the alpha' subunits of casein kinase II.";
RL   Biochemistry 29:8436-8447(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=8420794; DOI=10.1016/0014-5793(93)81197-8;
RA   Devilat I., Carvallo P.;
RT   "Structure and sequence of an intronless gene for human casein kinase II-
RT   alpha subunit.";
RL   FEBS Lett. 316:114-118(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, Muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PHOSPHORYLATION AT THR-344; THR-360; SER-362 AND SER-370.
RX   PubMed=7592773; DOI=10.1074/jbc.270.43.25872;
RA   Bosc D.G., Slominski E., Sichler C., Litchfield D.W.;
RT   "Phosphorylation of casein kinase II by p34cdc2. Identification of
RT   phosphorylation sites using phosphorylation site mutants in vitro.";
RL   J. Biol. Chem. 270:25872-25878(1995).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R.,
RA   Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16,
RT   and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [12]
RP   FUNCTION IN CELL CYCLE.
RX   PubMed=11704824; DOI=10.1038/sj.onc.1204894;
RA   Sayed M., Pelech S., Wong C., Marotta A., Salh B.;
RT   "Protein kinase CK2 is involved in G2 arrest and apoptosis following
RT   spindle damage in epithelial cells.";
RL   Oncogene 20:6994-7005(2001).
RN   [13]
RP   INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=12393879; DOI=10.1074/jbc.m209820200;
RA   Keller D.M., Lu H.;
RT   "p53 serine 392 phosphorylation increases after UV through induction of the
RT   assembly of the CK2.hSPT16.SSRP1 complex.";
RL   J. Biol. Chem. 277:50206-50213(2002).
RN   [14]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=16193064; DOI=10.1038/sj.emboj.7600827;
RA   Shin S., Lee Y., Kim W., Ko H., Choi H., Kim K.;
RT   "Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing
RT   procaspase-8.";
RL   EMBO J. 24:3532-3542(2005).
RN   [15]
RP   INTERACTION WITH RNPS1.
RX   PubMed=15684395; DOI=10.1128/mcb.25.4.1446-1457.2005;
RA   Trembley J.H., Tatsumi S., Sakashita E., Loyer P., Slaughter C.A.,
RA   Suzuki H., Endo H., Kidd V.J., Mayeda A.;
RT   "Activation of pre-mRNA splicing by human RNPS1 is regulated by CK2
RT   phosphorylation.";
RL   Mol. Cell. Biol. 25:1446-1457(2005).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   FUNCTION IN CELL CYCLE.
RX   PubMed=19188443; DOI=10.1128/mcb.01563-08;
RA   St-Denis N.A., Derksen D.R., Litchfield D.W.;
RT   "Evidence for regulation of mitotic progression through temporal
RT   phosphorylation and dephosphorylation of CK2alpha.";
RL   Mol. Cell. Biol. 29:2068-2081(2009).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=12631575; DOI=10.1096/fj.02-0473rev;
RA   Meggio F., Pinna L.A.;
RT   "One-thousand-and-one substrates of protein kinase CK2?";
RL   FASEB J. 17:349-368(2003).
RN   [19]
RP   REVIEW ON STRUCTURE.
RX   PubMed=19387553; DOI=10.1007/s00018-009-9149-8;
RA   Niefind K., Raaf J., Issinger O.G.;
RT   "Protein kinase CK2 in health and disease: Protein kinase CK2: from
RT   structures to insights.";
RL   Cell. Mol. Life Sci. 66:1800-1816(2009).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387552; DOI=10.1007/s00018-009-9150-2;
RA   St-Denis N.A., Litchfield D.W.;
RT   "Protein kinase CK2 in health and disease: From birth to death: the role of
RT   protein kinase CK2 in the regulation of cell proliferation and survival.";
RL   Cell. Mol. Life Sci. 66:1817-1829(2009).
RN   [21]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387551; DOI=10.1007/s00018-009-9151-1;
RA   Filhol O., Cochet C.;
RT   "Protein kinase CK2 in health and disease: Cellular functions of protein
RT   kinase CK2: a dynamic affair.";
RL   Cell. Mol. Life Sci. 66:1830-1839(2009).
RN   [22]
RP   REVIEW ON FUNCTION IN REGULATION OF HSP90.
RX   PubMed=19387550; DOI=10.1007/s00018-009-9152-0;
RA   Miyata Y.;
RT   "Protein kinase CK2 in health and disease: CK2: the kinase controlling the
RT   Hsp90 chaperone machinery.";
RL   Cell. Mol. Life Sci. 66:1840-1849(2009).
RN   [23]
RP   REVIEW ON FUNCTION IN WNT SIGNALING.
RX   PubMed=19387549; DOI=10.1007/s00018-009-9153-z;
RA   Dominguez I., Sonenshein G.E., Seldin D.C.;
RT   "Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-
RT   kappaB signaling: linking development and cancer.";
RL   Cell. Mol. Life Sci. 66:1850-1857(2009).
RN   [24]
RP   INTERACTION WITH SNAI1.
RX   PubMed=19923321; DOI=10.1091/mbc.e09-06-0504;
RA   MacPherson M.R., Molina P., Souchelnytskyi S., Wernstedt C.,
RA   Martin-Perez J., Portillo F., Cano A.;
RT   "Phosphorylation of serine 11 and serine 92 as new positive regulators of
RT   human Snail1 function: potential involvement of casein kinase-2 and the
RT   cAMP-activated kinase protein kinase A.";
RL   Mol. Biol. Cell 21:244-253(2010).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH PML.
RX   PubMed=20625391; DOI=10.1371/journal.pone.0011418;
RA   Hung M.S., Lin Y.C., Mao J.H., Kim I.J., Xu Z., Yang C.T., Jablons D.M.,
RA   You L.;
RT   "Functional polymorphism of the CK2alpha intronless gene plays oncogenic
RT   roles in lung cancer.";
RL   PLoS ONE 5:E11418-E11418(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH PML.
RX   PubMed=22406621; DOI=10.1158/0008-5472.can-11-3159;
RA   Rabellino A., Carter B., Konstantinidou G., Wu S.Y., Rimessi A.,
RA   Byers L.A., Heymach J.V., Girard L., Chiang C.M., Teruya-Feldstein J.,
RA   Scaglioni P.P.;
RT   "The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its
RT   oncogenic counterpart PML-RARA.";
RL   Cancer Res. 72:2275-2284(2012).
RN   [29]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22184066; DOI=10.1128/mcb.06466-11;
RA   Riman S., Rizkallah R., Kassardjian A., Alexander K.E., Luescher B.,
RA   Hurt M.M.;
RT   "Phosphorylation of the transcription factor YY1 by CK2alpha prevents
RT   cleavage by caspase 7 during apoptosis.";
RL   Mol. Cell. Biol. 32:797-807(2012).
RN   [30]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=23123191; DOI=10.1016/j.bbamcr.2012.10.025;
RA   Ampofo E., Sokolowsky T., Goetz C., Montenarh M.;
RT   "Functional interaction of protein kinase CK2 and activating transcription
RT   factor 4 (ATF4), a key player in the cellular stress response.";
RL   Biochim. Biophys. Acta 1833:439-451(2013).
RN   [31]
RP   FUNCTION, INTERACTION WITH CCAR2, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=24962073; DOI=10.1002/ijc.29043;
RA   Bae J.S., Park S.H., Kim K.M., Kwon K.S., Kim C.Y., Lee H.K., Park B.H.,
RA   Park H.S., Lee H., Moon W.S., Chung M.J., Sylvester K.G., Jang K.Y.;
RT   "CK2alpha phosphorylates DBC1 and is involved in the progression of gastric
RT   carcinoma and predicts poor survival of gastric carcinoma patients.";
RL   Int. J. Cancer 136:797-809(2015).
RN   [32]
RP   INVOLVEMENT IN OCNDS, AND VARIANTS OCNDS GLN-47; SER-50; GLY-175 AND
RP   ARG-198.
RX   PubMed=27048600; DOI=10.1007/s00439-016-1661-y;
RA   Okur V., Cho M.T., Henderson L., Retterer K., Schneider M., Sattler S.,
RA   Niyazov D., Azage M., Smith S., Picker J., Lincoln S., Tarnopolsky M.,
RA   Brady L., Bjornsson H.T., Applegate C., Dameron A., Willaert R., Baskin B.,
RA   Juusola J., Chung W.K.;
RT   "De novo mutations in CSNK2A1 are associated with neurodevelopmental
RT   abnormalities and dysmorphic features.";
RL   Hum. Genet. 135:699-705(2016).
RN   [33]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30699359; DOI=10.1016/j.celrep.2019.01.018;
RA   Sager R.A., Woodford M.R., Backe S.J., Makedon A.M., Baker-Williams A.J.,
RA   DiGregorio B.T., Loiselle D.R., Haystead T.A., Zachara N.E., Prodromou C.,
RA   Bourboulia D., Schmidt L.S., Linehan W.M., Bratslavsky G., Mollapour M.;
RT   "Post-translational regulation of FNIP1 creates a rheostat for the
RT   molecular chaperone Hsp90.";
RL   Cell Rep. 26:1344-1356(2019).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-337, AND SUBUNIT.
RX   PubMed=11092945; DOI=10.1107/s0907444900013627;
RA   Niefind K., Guerra B., Ermakowa I., Issinger O.G.;
RT   "Crystallization and preliminary characterization of crystals of human
RT   protein kinase CK2.";
RL   Acta Crystallogr. D 56:1680-1684(2000).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-337 IN COMPLEX WITH CSNK2B, AND
RP   SUBUNIT.
RX   PubMed=11574463; DOI=10.1093/emboj/20.19.5320;
RA   Niefind K., Guerra B., Ermakowa I., Issinger O.G.;
RT   "Crystal structure of human protein kinase CK2: insights into basic
RT   properties of the CK2 holoenzyme.";
RL   EMBO J. 20:5320-5331(2001).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-329.
RX   PubMed=14646071; DOI=10.1107/s0907444903018900;
RA   Pechkova E., Zanotti G., Nicolini C.;
RT   "Three-dimensional atomic structure of a catalytic subunit mutant of human
RT   protein kinase CK2.";
RL   Acta Crystallogr. D 59:2133-2139(2003).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2-335.
RX   PubMed=12860116; DOI=10.1016/s0022-2836(03)00638-7;
RA   Ermakova I., Boldyreff B., Issinger O.G., Niefind K.;
RT   "Crystal structure of a C-terminal deletion mutant of human protein kinase
RT   CK2 catalytic subunit.";
RL   J. Mol. Biol. 330:925-934(2003).
CC   -!- FUNCTION: Catalytic subunit of a constitutively active
CC       serine/threonine-protein kinase complex that phosphorylates a large
CC       number of substrates containing acidic residues C-terminal to the
CC       phosphorylated serine or threonine (PubMed:11239457, PubMed:11704824,
CC       PubMed:16193064, PubMed:19188443, PubMed:20625391, PubMed:22406621,
CC       PubMed:24962073). Regulates numerous cellular processes, such as cell
CC       cycle progression, apoptosis and transcription, as well as viral
CC       infection (PubMed:12631575, PubMed:19387552, PubMed:19387551). May act
CC       as a regulatory node which integrates and coordinates numerous signals
CC       leading to an appropriate cellular response (PubMed:12631575,
CC       PubMed:19387552, PubMed:19387551). During mitosis, functions as a
CC       component of the p53/TP53-dependent spindle assembly checkpoint (SAC)
CC       that maintains cyclin-B-CDK1 activity and G2 arrest in response to
CC       spindle damage (PubMed:11704824, PubMed:19188443). Also required for
CC       p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53
CC       following UV irradiation. Can also negatively regulate apoptosis
CC       (PubMed:11239457). Phosphorylates the caspases CASP9 and CASP2 and the
CC       apoptotic regulator NOL3 (PubMed:16193064). Phosphorylation protects
CC       CASP9 from cleavage and activation by CASP8, and inhibits the
CC       dimerization of CASP2 and activation of CASP8 (PubMed:16193064).
CC       Phosphorylates YY1, protecting YY1 from cleavage by CASP7 during
CC       apoptosis (PubMed:22184066). Regulates transcription by direct
CC       phosphorylation of RNA polymerases I, II, III and IV (PubMed:19387550,
CC       PubMed:12631575, PubMed:19387552, PubMed:19387551, PubMed:23123191).
CC       Also phosphorylates and regulates numerous transcription factors
CC       including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, ATF4, SRF, MAX,
CC       JUN, FOS, MYC and MYB (PubMed:19387550, PubMed:12631575,
CC       PubMed:19387552, PubMed:19387551, PubMed:23123191). Phosphorylates
CC       Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for
CC       chaperone function (PubMed:19387550). Mediates sequential
CC       phosphorylation of FNIP1, promoting its gradual interaction with Hsp90,
CC       leading to activate both kinase and non-kinase client proteins of Hsp90
CC       (PubMed:30699359). Regulates Wnt signaling by phosphorylating CTNNB1
CC       and the transcription factor LEF1 (PubMed:19387549). Acts as an
CC       ectokinase that phosphorylates several extracellular proteins
CC       (PubMed:19387550, PubMed:12631575, PubMed:19387552, PubMed:19387551).
CC       During viral infection, phosphorylates various proteins involved in the
CC       viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV
CC       (PubMed:19387550, PubMed:12631575, PubMed:19387552, PubMed:19387551).
CC       Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated
CC       degradation (PubMed:20625391, PubMed:22406621). Plays an important role
CC       in the circadian clock function by phosphorylating ARNTL/BMAL1 at 'Ser-
CC       90' which is pivotal for its interaction with CLOCK and which controls
CC       CLOCK nuclear entry (By similarity). Phosphorylates CCAR2 at 'Thr-454'
CC       in gastric carcinoma tissue (PubMed:24962073).
CC       {ECO:0000250|UniProtKB:P19139, ECO:0000269|PubMed:11239457,
CC       ECO:0000269|PubMed:11704824, ECO:0000269|PubMed:16193064,
CC       ECO:0000269|PubMed:19188443, ECO:0000269|PubMed:20625391,
CC       ECO:0000269|PubMed:22184066, ECO:0000269|PubMed:22406621,
CC       ECO:0000269|PubMed:23123191, ECO:0000269|PubMed:24962073,
CC       ECO:0000269|PubMed:30699359, ECO:0000303|PubMed:12631575,
CC       ECO:0000303|PubMed:19387549, ECO:0000303|PubMed:19387550,
CC       ECO:0000303|PubMed:19387551, ECO:0000303|PubMed:19387552}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:20625391, ECO:0000269|PubMed:22184066,
CC         ECO:0000269|PubMed:23123191, ECO:0000269|PubMed:30699359};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:23123191, ECO:0000269|PubMed:30699359};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:20625391};
CC   -!- ACTIVITY REGULATION: Constitutively active protein kinase whose
CC       activity is not directly affected by phosphorylation. Seems to be
CC       regulated by level of expression and localization.
CC   -!- SUBUNIT: Heterotetramer composed of two catalytic subunits (alpha chain
CC       and/or alpha' chain) and two regulatory subunits (beta chains). The
CC       tetramer can exist as a combination of 2 alpha/2 beta, 2 alpha'/2 beta
CC       or 1 alpha/1 alpha'/2 beta subunits. Also part of a CK2-SPT16-SSRP1
CC       complex composed of SSRP1, SUPT16H, CSNK2A1, CSNK2A2 and CSNK2B, which
CC       forms following UV irradiation. Interacts with RNPS1. Interacts with
CC       SNAI1. Interacts with PML (isoform PML-12). Interacts with CCAR2.
CC       {ECO:0000269|PubMed:11092945, ECO:0000269|PubMed:11239457,
CC       ECO:0000269|PubMed:11574463, ECO:0000269|PubMed:12393879,
CC       ECO:0000269|PubMed:15684395, ECO:0000269|PubMed:19923321,
CC       ECO:0000269|PubMed:20625391, ECO:0000269|PubMed:22406621,
CC       ECO:0000269|PubMed:24962073}.
CC   -!- INTERACTION:
CC       P68400; P78563: ADARB1; NbExp=3; IntAct=EBI-347804, EBI-2967304;
CC       P68400; P05067: APP; NbExp=3; IntAct=EBI-347804, EBI-77613;
CC       P68400; Q86V38: ATN1; NbExp=6; IntAct=EBI-347804, EBI-11954292;
CC       P68400; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-347804, EBI-10181188;
CC       P68400; P35226: BMI1; NbExp=2; IntAct=EBI-347804, EBI-2341576;
CC       P68400; O00257-3: CBX4; NbExp=2; IntAct=EBI-347804, EBI-4392727;
CC       P68400; Q8IYX3: CCDC116; NbExp=3; IntAct=EBI-347804, EBI-744311;
CC       P68400; P68400: CSNK2A1; NbExp=4; IntAct=EBI-347804, EBI-347804;
CC       P68400; P19784: CSNK2A2; NbExp=10; IntAct=EBI-347804, EBI-347451;
CC       P68400; P67870: CSNK2B; NbExp=27; IntAct=EBI-347804, EBI-348169;
CC       P68400; Q5HYN5: CT45A1; NbExp=3; IntAct=EBI-347804, EBI-12051833;
CC       P68400; Q9GZR7: DDX24; NbExp=2; IntAct=EBI-347804, EBI-713081;
CC       P68400; P35659: DEK; NbExp=2; IntAct=EBI-347804, EBI-301977;
CC       P68400; Q92997: DVL3; NbExp=4; IntAct=EBI-347804, EBI-739789;
CC       P68400; O75822: EIF3J; NbExp=3; IntAct=EBI-347804, EBI-366647;
CC       P68400; Q8N9E0: FAM133A; NbExp=5; IntAct=EBI-347804, EBI-10268158;
CC       P68400; A0A0C3SFZ9: FCHO1; NbExp=3; IntAct=EBI-347804, EBI-11977403;
CC       P68400; Q9NW75-2: GPATCH2; NbExp=3; IntAct=EBI-347804, EBI-12068108;
CC       P68400; Q9NWQ4-1: GPATCH2L; NbExp=6; IntAct=EBI-347804, EBI-11959863;
CC       P68400; O15499: GSC2; NbExp=3; IntAct=EBI-347804, EBI-19954058;
CC       P68400; Q13547: HDAC1; NbExp=3; IntAct=EBI-347804, EBI-301834;
CC       P68400; P09017: HOXC4; NbExp=3; IntAct=EBI-347804, EBI-3923226;
CC       P68400; A0A0C4DFT8: JADE2; NbExp=3; IntAct=EBI-347804, EBI-12094820;
CC       P68400; Q14145: KEAP1; NbExp=3; IntAct=EBI-347804, EBI-751001;
CC       P68400; Q5T7B8-2: KIF24; NbExp=3; IntAct=EBI-347804, EBI-10213781;
CC       P68400; O60282: KIF5C; NbExp=4; IntAct=EBI-347804, EBI-717170;
CC       P68400; Q92876: KLK6; NbExp=3; IntAct=EBI-347804, EBI-2432309;
CC       P68400; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-347804, EBI-12039345;
CC       P68400; Q68G74: LHX8; NbExp=3; IntAct=EBI-347804, EBI-8474075;
CC       P68400; Q9NQ69: LHX9; NbExp=3; IntAct=EBI-347804, EBI-10175218;
CC       P68400; P43364-2: MAGEA11; NbExp=3; IntAct=EBI-347804, EBI-10178634;
CC       P68400; P50221: MEOX1; NbExp=3; IntAct=EBI-347804, EBI-2864512;
CC       P68400; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-347804, EBI-16439278;
CC       P68400; Q9BU76: MMTAG2; NbExp=4; IntAct=EBI-347804, EBI-742459;
CC       P68400; P23511: NFYA; NbExp=4; IntAct=EBI-347804, EBI-389739;
CC       P68400; P23511-2: NFYA; NbExp=3; IntAct=EBI-347804, EBI-11061759;
CC       P68400; Q02548: PAX5; NbExp=3; IntAct=EBI-347804, EBI-296331;
CC       P68400; P26367: PAX6; NbExp=5; IntAct=EBI-347804, EBI-747278;
CC       P68400; Q5T6S3: PHF19; NbExp=3; IntAct=EBI-347804, EBI-2339674;
CC       P68400; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-347804, EBI-11532361;
CC       P68400; P29590: PML; NbExp=2; IntAct=EBI-347804, EBI-295890;
CC       P68400; Q9H307: PNN; NbExp=2; IntAct=EBI-347804, EBI-681904;
CC       P68400; P78424: POU6F2; NbExp=3; IntAct=EBI-347804, EBI-12029004;
CC       P68400; O75400-2: PRPF40A; NbExp=2; IntAct=EBI-347804, EBI-5280197;
CC       P68400; Q14498: RBM39; NbExp=3; IntAct=EBI-347804, EBI-395290;
CC       P68400; Q04864-2: REL; NbExp=3; IntAct=EBI-347804, EBI-10829018;
CC       P68400; Q6ZNA4: RNF111; NbExp=6; IntAct=EBI-347804, EBI-2129175;
CC       P68400; Q99496: RNF2; NbExp=4; IntAct=EBI-347804, EBI-722416;
CC       P68400; Q96EB6: SIRT1; NbExp=5; IntAct=EBI-347804, EBI-1802965;
CC       P68400; Q92504: SLC39A7; NbExp=4; IntAct=EBI-347804, EBI-1051105;
CC       P68400; O43623: SNAI2; NbExp=3; IntAct=EBI-347804, EBI-9876238;
CC       P68400; P12931: SRC; NbExp=2; IntAct=EBI-347804, EBI-621482;
CC       P68400; Q08945: SSRP1; NbExp=3; IntAct=EBI-347804, EBI-353771;
CC       P68400; Q96MF2: STAC3; NbExp=7; IntAct=EBI-347804, EBI-745680;
CC       P68400; O75683: SURF6; NbExp=2; IntAct=EBI-347804, EBI-2691252;
CC       P68400; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-347804, EBI-11139477;
CC       P68400; Q9NVV9: THAP1; NbExp=7; IntAct=EBI-347804, EBI-741515;
CC       P68400; Q9Y2W1: THRAP3; NbExp=2; IntAct=EBI-347804, EBI-352039;
CC       P68400; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347804, EBI-11741437;
CC       P68400; Q8WV44: TRIM41; NbExp=3; IntAct=EBI-347804, EBI-725997;
CC       P68400; Q9H2G4: TSPYL2; NbExp=4; IntAct=EBI-347804, EBI-947459;
CC       P68400; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-347804, EBI-12272076;
CC       P68400; Q8IYI8: ZNF440; NbExp=3; IntAct=EBI-347804, EBI-726439;
CC       P68400; Q96NG5: ZNF558; NbExp=3; IntAct=EBI-347804, EBI-373363;
CC       P68400; Q9BS34: ZNF670; NbExp=3; IntAct=EBI-347804, EBI-745276;
CC       P68400; Q6NSZ9-2: ZSCAN25; NbExp=3; IntAct=EBI-347804, EBI-14650477;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23123191,
CC       ECO:0000269|PubMed:24962073}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P68400-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P68400-2; Sequence=VSP_041925;
CC   -!- TISSUE SPECIFICITY: Expressed in gastric carcinoma tissue and the
CC       expression gradually increases with the progression of the carcinoma
CC       (at protein level). {ECO:0000269|PubMed:24962073}.
CC   -!- PTM: Phosphorylated at Thr-344, Thr-360, Ser-362 and Ser-370 by CDK1 in
CC       prophase and metaphase and dephosphorylated during anaphase.
CC       Phosphorylation does not directly affect casein kinase 2 activity, but
CC       may contribute to its regulation by forming binding sites for
CC       interacting proteins and/or targeting it to different compartments.
CC       {ECO:0000269|PubMed:7592773}.
CC   -!- DISEASE: Okur-Chung neurodevelopmental syndrome (OCNDS) [MIM:617062]:
CC       An autosomal dominant neurodevelopmental disorder characterized by
CC       developmental delay, intellectual disability, behavioral problems,
CC       hypotonia, speech problems, microcephaly, pachygyria and variable
CC       dysmorphic features. {ECO:0000269|PubMed:27048600}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Can use both ATP and GTP as phosphoryl donors.
CC       Phosphorylation by casein kinase 2 has been estimated to represent up
CC       to one quarter of the eukaryotic phosphoproteome. Casein kinase 2 has
CC       been found to be increased at protein level and up-regulated at the
CC       level of enzyme activity in the majority of cancers. However, elevated
CC       levels of casein kinase 2 are present in certain normal organs such as
CC       brain and testes.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. CK2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J02853; AAA56821.1; -; mRNA.
DR   EMBL; M55265; AAA35503.1; -; mRNA.
DR   EMBL; S53149; ABB72474.1; -; mRNA.
DR   EMBL; X70251; CAA49758.1; -; Genomic_DNA.
DR   EMBL; AK302583; BAG63838.1; -; mRNA.
DR   EMBL; BT019792; AAV38595.1; -; mRNA.
DR   EMBL; AB451279; BAG70093.1; -; mRNA.
DR   EMBL; AL049761; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471133; EAX10665.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10666.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10667.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10668.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10669.1; -; Genomic_DNA.
DR   EMBL; BC011668; AAH11668.1; -; mRNA.
DR   EMBL; BC053532; AAH53532.1; -; mRNA.
DR   EMBL; BC071167; AAH71167.1; -; mRNA.
DR   CCDS; CCDS13003.1; -. [P68400-1]
DR   CCDS; CCDS13004.1; -. [P68400-2]
DR   PIR; A30319; A30319.
DR   RefSeq; NP_001886.1; NM_001895.3. [P68400-1]
DR   RefSeq; NP_808227.1; NM_177559.2. [P68400-1]
DR   RefSeq; NP_808228.1; NM_177560.2. [P68400-2]
DR   PDB; 1JWH; X-ray; 3.10 A; A/B=1-337.
DR   PDB; 1NA7; X-ray; 2.40 A; A=1-329.
DR   PDB; 1PJK; X-ray; 2.50 A; A=2-335.
DR   PDB; 2PVR; X-ray; 1.60 A; A=2-335.
DR   PDB; 2ZJW; X-ray; 2.40 A; A=1-335.
DR   PDB; 3AMY; X-ray; 2.30 A; A=1-335.
DR   PDB; 3AT2; X-ray; 1.60 A; A=1-335.
DR   PDB; 3AT3; X-ray; 2.60 A; A=1-335.
DR   PDB; 3AT4; X-ray; 2.20 A; A=1-335.
DR   PDB; 3AXW; X-ray; 2.50 A; A=1-335.
DR   PDB; 3BQC; X-ray; 1.50 A; A=1-335.
DR   PDB; 3C13; X-ray; 1.95 A; A=1-335.
DR   PDB; 3FWQ; X-ray; 2.30 A; A/B=1-335.
DR   PDB; 3H30; X-ray; 1.56 A; A/B=1-334.
DR   PDB; 3JUH; X-ray; 1.66 A; A/B=1-335.
DR   PDB; 3MB6; X-ray; 1.75 A; A=1-331.
DR   PDB; 3MB7; X-ray; 1.65 A; A=1-331.
DR   PDB; 3NGA; X-ray; 2.71 A; A/B=1-333.
DR   PDB; 3NSZ; X-ray; 1.30 A; A=2-331.
DR   PDB; 3OWJ; X-ray; 1.85 A; A=1-331.
DR   PDB; 3OWK; X-ray; 1.80 A; A=1-331.
DR   PDB; 3OWL; X-ray; 2.10 A; A=1-331.
DR   PDB; 3PE1; X-ray; 1.60 A; A=1-337.
DR   PDB; 3PE2; X-ray; 1.90 A; A=1-337.
DR   PDB; 3PE4; X-ray; 1.95 A; B/D=340-352.
DR   PDB; 3Q04; X-ray; 1.80 A; A=3-330.
DR   PDB; 3Q9W; X-ray; 1.70 A; A=1-336.
DR   PDB; 3Q9X; X-ray; 2.20 A; A/B=1-336.
DR   PDB; 3Q9Y; X-ray; 1.80 A; A=1-336.
DR   PDB; 3Q9Z; X-ray; 2.20 A; A/B=1-336.
DR   PDB; 3QA0; X-ray; 2.50 A; A/B=1-336.
DR   PDB; 3R0T; X-ray; 1.75 A; A=1-337.
DR   PDB; 3RPS; X-ray; 2.30 A; A/B=1-335.
DR   PDB; 3TAX; X-ray; 1.88 A; B/D=340-352.
DR   PDB; 3U4U; X-ray; 2.20 A; A=1-333.
DR   PDB; 3U87; X-ray; 2.90 A; A/B=1-325.
DR   PDB; 3U9C; X-ray; 3.20 A; A/B=1-335.
DR   PDB; 3W8L; X-ray; 2.40 A; A/B=1-335.
DR   PDB; 3WAR; X-ray; 1.04 A; A=1-335.
DR   PDB; 3WIK; X-ray; 2.00 A; A=1-335.
DR   PDB; 3WIL; X-ray; 2.90 A; A=1-335.
DR   PDB; 3WOW; X-ray; 2.50 A; A=1-335.
DR   PDB; 4DGL; X-ray; 3.00 A; C/D=1-335.
DR   PDB; 4FBX; X-ray; 2.33 A; A=1-335.
DR   PDB; 4GRB; X-ray; 2.15 A; A=1-333.
DR   PDB; 4GUB; X-ray; 2.20 A; A=1-333.
DR   PDB; 4GYW; X-ray; 1.70 A; B/D=340-352.
DR   PDB; 4GYY; X-ray; 1.85 A; B/D=340-352.
DR   PDB; 4GZ3; X-ray; 1.90 A; B/D=340-352.
DR   PDB; 4IB5; X-ray; 2.20 A; A/B/C=1-335.
DR   PDB; 4KWP; X-ray; 1.25 A; A=1-336.
DR   PDB; 4MD7; X-ray; 3.10 A; E/F/G/H=1-391.
DR   PDB; 4MD8; X-ray; 3.30 A; E/F/G/H=1-391.
DR   PDB; 4MD9; X-ray; 3.50 A; E/F/G/H/K/L/M/P=1-336.
DR   PDB; 4NH1; X-ray; 3.30 A; A/B=1-335.
DR   PDB; 4RLL; X-ray; 1.85 A; A=1-335.
DR   PDB; 4UB7; X-ray; 2.10 A; A=1-335.
DR   PDB; 4UBA; X-ray; 3.00 A; A/B=1-335.
DR   PDB; 5B0X; X-ray; 2.30 A; A=1-335.
DR   PDB; 5CLP; X-ray; 1.68 A; A/B=2-329.
DR   PDB; 5CQU; X-ray; 2.35 A; A=1-335.
DR   PDB; 5CQW; X-ray; 2.65 A; A/B=1-335.
DR   PDB; 5CS6; X-ray; 1.88 A; A/B=2-329.
DR   PDB; 5CSH; X-ray; 1.59 A; A/B=2-329.
DR   PDB; 5CSP; X-ray; 1.50 A; A=2-329.
DR   PDB; 5CSV; X-ray; 1.38 A; A=2-329.
DR   PDB; 5CT0; X-ray; 2.01 A; A/B=2-329.
DR   PDB; 5CTP; X-ray; 2.03 A; A/B=2-329.
DR   PDB; 5CU0; X-ray; 2.18 A; A/B=2-329.
DR   PDB; 5CU2; X-ray; 1.71 A; A/B=2-329.
DR   PDB; 5CU3; X-ray; 1.79 A; A/B=2-329.
DR   PDB; 5CU4; X-ray; 1.56 A; A=2-329.
DR   PDB; 5CU6; X-ray; 1.36 A; A=2-329.
DR   PDB; 5CVF; X-ray; 1.63 A; A=2-329.
DR   PDB; 5CVG; X-ray; 1.25 A; A=2-329.
DR   PDB; 5CVH; X-ray; 1.85 A; A/B=2-329.
DR   PDB; 5CX9; X-ray; 1.73 A; A/B=2-329.
DR   PDB; 5H8B; X-ray; 2.55 A; A/B=1-333.
DR   PDB; 5H8E; X-ray; 2.15 A; A/B=1-333.
DR   PDB; 5H8G; X-ray; 2.00 A; A=1-333.
DR   PDB; 5HGV; X-ray; 2.05 A; B/D=340-352.
DR   PDB; 5KU8; X-ray; 2.22 A; A/B=2-332.
DR   PDB; 5KWH; X-ray; 2.12 A; A/B=1-333.
DR   PDB; 5M44; X-ray; 2.71 A; A=1-335.
DR   PDB; 5M4C; X-ray; 1.94 A; A=1-335.
DR   PDB; 5M4F; X-ray; 1.52 A; A=1-335.
DR   PDB; 5M4I; X-ray; 2.22 A; A=1-335.
DR   PDB; 5MMF; X-ray; 1.99 A; A/B=2-329.
DR   PDB; 5MMR; X-ray; 2.00 A; A/B=2-329.
DR   PDB; 5MO5; X-ray; 2.04 A; A/B=2-329.
DR   PDB; 5MO6; X-ray; 1.82 A; A/B=2-329.
DR   PDB; 5MO7; X-ray; 2.15 A; A/B=2-329.
DR   PDB; 5MO8; X-ray; 1.82 A; A/B=2-329.
DR   PDB; 5MOD; X-ray; 2.08 A; A/B=2-329.
DR   PDB; 5MOE; X-ray; 1.89 A; A/B=2-329.
DR   PDB; 5MOH; X-ray; 1.38 A; A=2-329.
DR   PDB; 5MOT; X-ray; 2.09 A; A=2-329.
DR   PDB; 5MOV; X-ray; 2.20 A; A=3-327.
DR   PDB; 5MOW; X-ray; 1.86 A; A/B=2-329.
DR   PDB; 5MP8; X-ray; 1.92 A; A/B=2-329.
DR   PDB; 5MPJ; X-ray; 2.14 A; A/B=2-329.
DR   PDB; 5N1V; X-ray; 2.52 A; A/B=1-336.
DR   PDB; 5N9K; X-ray; 1.64 A; A=1-335.
DR   PDB; 5N9L; X-ray; 1.79 A; A=1-335.
DR   PDB; 5N9N; X-ray; 1.84 A; A=1-335.
DR   PDB; 5NQC; X-ray; 2.00 A; A=2-335.
DR   PDB; 5OMY; X-ray; 1.95 A; A=1-391.
DR   PDB; 5ONI; X-ray; 2.00 A; A/B=1-391.
DR   PDB; 5OQU; X-ray; 2.32 A; A/B=2-329.
DR   PDB; 5ORH; X-ray; 1.75 A; A/B=2-329.
DR   PDB; 5ORJ; X-ray; 1.99 A; A/B=2-329.
DR   PDB; 5ORK; X-ray; 2.14 A; A/B=2-329.
DR   PDB; 5OS7; X-ray; 1.66 A; A/B=2-329.
DR   PDB; 5OS8; X-ray; 1.55 A; A=2-329.
DR   PDB; 5OSL; X-ray; 1.95 A; A=2-329.
DR   PDB; 5OSP; X-ray; 1.91 A; A=2-329.
DR   PDB; 5OSR; X-ray; 1.57 A; A=2-329.
DR   PDB; 5OSU; X-ray; 1.63 A; A=2-329.
DR   PDB; 5OSZ; X-ray; 2.00 A; A=2-329.
DR   PDB; 5OT5; X-ray; 1.63 A; A/B=2-329.
DR   PDB; 5OT6; X-ray; 1.94 A; A/B=2-329.
DR   PDB; 5OTD; X-ray; 1.57 A; A/B=2-329.
DR   PDB; 5OTH; X-ray; 1.69 A; A/B=2-329.
DR   PDB; 5OTI; X-ray; 1.59 A; A=2-329.
DR   PDB; 5OTL; X-ray; 1.57 A; A/B=2-329.
DR   PDB; 5OTO; X-ray; 1.51 A; A/B=2-329.
DR   PDB; 5OTP; X-ray; 1.57 A; A/B=2-329.
DR   PDB; 5OTQ; X-ray; 1.38 A; A=2-329.
DR   PDB; 5OTR; X-ray; 1.52 A; A=2-329.
DR   PDB; 5OTS; X-ray; 1.90 A; A=2-329.
DR   PDB; 5OTY; X-ray; 1.48 A; A=2-329.
DR   PDB; 5OTZ; X-ray; 1.46 A; A=2-329.
DR   PDB; 5OUE; X-ray; 2.01 A; A/B=2-329.
DR   PDB; 5OUL; X-ray; 1.34 A; A=2-329.
DR   PDB; 5OUM; X-ray; 2.05 A; A/B=2-329.
DR   PDB; 5OUU; X-ray; 1.81 A; A/B=2-329.
DR   PDB; 5OWH; X-ray; 2.30 A; A=1-335.
DR   PDB; 5OWL; X-ray; 2.23 A; A/B=1-335.
DR   PDB; 5OYF; X-ray; 1.54 A; A=2-329.
DR   PDB; 5T1H; X-ray; 2.11 A; A/B=1-333.
DR   PDB; 5VIE; X-ray; 2.60 A; B/D=339-352.
DR   PDB; 5VIF; X-ray; 2.25 A; B=339-352.
DR   PDB; 5ZN0; Other; 1.10 A; A=1-329.
DR   PDB; 5ZN1; X-ray; 1.05 A; A=1-329.
DR   PDB; 5ZN2; X-ray; 1.20 A; A=1-329.
DR   PDB; 5ZN3; X-ray; 1.50 A; A=1-329.
DR   PDB; 5ZN4; X-ray; 1.65 A; A=1-329.
DR   PDB; 5ZN5; X-ray; 1.70 A; A=1-329.
DR   PDB; 6A1C; X-ray; 1.68 A; A=1-335.
DR   PDB; 6E37; X-ray; 2.53 A; B=339-352.
DR   PDB; 6EHK; X-ray; 1.40 A; A=2-329.
DR   PDB; 6EHU; X-ray; 1.95 A; A/B=2-329.
DR   PDB; 6EII; X-ray; 1.94 A; A/B=2-329.
DR   PDB; 6FVF; X-ray; 1.47 A; A=2-329.
DR   PDB; 6FVG; X-ray; 1.60 A; A=2-329.
DR   PDB; 6GIH; X-ray; 1.96 A; A=2-329.
DR   PDB; 6GMD; X-ray; 1.66 A; A/B=2-329.
DR   PDB; 6HBN; X-ray; 1.59 A; A/B=1-335.
DR   PDB; 6HME; X-ray; 1.85 A; A/B=1-335.
DR   PDB; 6HNW; X-ray; 2.00 A; A=1-336.
DR   PDB; 6HNY; X-ray; 1.65 A; A=1-336.
DR   PDB; 6HOP; X-ray; 1.55 A; A=1-336.
DR   PDB; 6HOQ; X-ray; 1.55 A; A=1-336.
DR   PDB; 6HOR; X-ray; 1.80 A; A=1-336.
DR   PDB; 6HOT; X-ray; 1.50 A; A=1-336.
DR   PDB; 6HOU; X-ray; 1.80 A; A=1-336.
DR   PDB; 6JWA; X-ray; 1.78 A; A=1-335.
DR   PDB; 6L1Z; X-ray; 1.91 A; A=1-335.
DR   PDB; 6L21; X-ray; 2.05 A; A=1-335.
DR   PDB; 6L22; X-ray; 2.12 A; A=1-335.
DR   PDB; 6L23; X-ray; 1.97 A; A=1-335.
DR   PDB; 6L24; X-ray; 2.40 A; A=1-335.
DR   PDB; 6Q38; X-ray; 1.74 A; A=3-329.
DR   PDB; 6Q4Q; X-ray; 1.45 A; A/B=3-329.
DR   PDB; 6QY7; X-ray; 2.10 A; A/B=1-337.
DR   PDB; 6RB1; X-ray; 1.50 A; A=1-336.
DR   PDB; 6RCB; X-ray; 2.05 A; A=1-336.
DR   PDB; 6RCM; X-ray; 1.70 A; A=1-336.
DR   PDB; 6RFE; X-ray; 1.54 A; A=1-336.
DR   PDB; 6RFF; X-ray; 1.80 A; A=1-336.
DR   PDB; 6SPW; X-ray; 1.60 A; A=1-391.
DR   PDB; 6SPX; X-ray; 1.99 A; A=1-335.
DR   PDB; 6TEI; X-ray; 1.76 A; A/B=1-335.
DR   PDB; 6TLL; X-ray; 1.88 A; A=1-391.
DR   PDB; 6TLO; X-ray; 1.69 A; A=1-391.
DR   PDB; 6TLP; X-ray; 1.93 A; A=1-391.
DR   PDB; 6TLR; X-ray; 1.64 A; A=1-391.
DR   PDB; 6TLS; X-ray; 1.46 A; A=1-391.
DR   PDB; 6TLU; X-ray; 1.81 A; AAA=1-391.
DR   PDB; 6TLV; X-ray; 1.67 A; A=1-391.
DR   PDB; 6TLW; X-ray; 1.73 A; A=1-391.
DR   PDB; 6YPG; X-ray; 1.51 A; A=2-329.
DR   PDB; 6YPH; X-ray; 1.67 A; A/B=2-329.
DR   PDB; 6YPJ; X-ray; 1.64 A; A=2-329.
DR   PDB; 6YPK; X-ray; 1.79 A; A=2-329.
DR   PDB; 6YPN; X-ray; 1.58 A; B=1-329.
DR   PDB; 6YUL; X-ray; 2.40 A; AAA/GGG=1-391.
DR   PDB; 6YUM; X-ray; 2.75 A; AAA/GGG=1-391.
DR   PDB; 6YZH; X-ray; 1.19 A; A=3-329.
DR   PDB; 6Z19; X-ray; 1.47 A; B=2-329.
DR   PDB; 6Z83; X-ray; 2.17 A; AAA/BBB=1-337.
DR   PDB; 6Z84; X-ray; 2.50 A; AAA/BBB=1-337.
DR   PDB; 7A49; X-ray; 2.03 A; A/B=1-335.
DR   PDB; 7A4B; X-ray; 2.06 A; A/B=1-335.
DR   PDB; 7A4C; X-ray; 2.50 A; A/B=1-335.
DR   PDB; 7AT5; X-ray; 1.77 A; A/B=1-335.
DR   PDB; 7AY9; X-ray; 2.25 A; A/B=1-336.
DR   PDB; 7AYA; X-ray; 2.45 A; A/B=1-336.
DR   PDB; 7B8H; X-ray; 1.34 A; A=1-335.
DR   PDB; 7B8I; X-ray; 2.55 A; A/B=1-335.
DR   PDB; 7BU4; X-ray; 1.70 A; A=1-335.
DR   PDB; 7L1X; X-ray; 1.80 A; A=2-335.
DR   PDB; 7PSU; X-ray; 1.77 A; A/B=1-391.
DR   PDBsum; 1JWH; -.
DR   PDBsum; 1NA7; -.
DR   PDBsum; 1PJK; -.
DR   PDBsum; 2PVR; -.
DR   PDBsum; 2ZJW; -.
DR   PDBsum; 3AMY; -.
DR   PDBsum; 3AT2; -.
DR   PDBsum; 3AT3; -.
DR   PDBsum; 3AT4; -.
DR   PDBsum; 3AXW; -.
DR   PDBsum; 3BQC; -.
DR   PDBsum; 3C13; -.
DR   PDBsum; 3FWQ; -.
DR   PDBsum; 3H30; -.
DR   PDBsum; 3JUH; -.
DR   PDBsum; 3MB6; -.
DR   PDBsum; 3MB7; -.
DR   PDBsum; 3NGA; -.
DR   PDBsum; 3NSZ; -.
DR   PDBsum; 3OWJ; -.
DR   PDBsum; 3OWK; -.
DR   PDBsum; 3OWL; -.
DR   PDBsum; 3PE1; -.
DR   PDBsum; 3PE2; -.
DR   PDBsum; 3PE4; -.
DR   PDBsum; 3Q04; -.
DR   PDBsum; 3Q9W; -.
DR   PDBsum; 3Q9X; -.
DR   PDBsum; 3Q9Y; -.
DR   PDBsum; 3Q9Z; -.
DR   PDBsum; 3QA0; -.
DR   PDBsum; 3R0T; -.
DR   PDBsum; 3RPS; -.
DR   PDBsum; 3TAX; -.
DR   PDBsum; 3U4U; -.
DR   PDBsum; 3U87; -.
DR   PDBsum; 3U9C; -.
DR   PDBsum; 3W8L; -.
DR   PDBsum; 3WAR; -.
DR   PDBsum; 3WIK; -.
DR   PDBsum; 3WIL; -.
DR   PDBsum; 3WOW; -.
DR   PDBsum; 4DGL; -.
DR   PDBsum; 4FBX; -.
DR   PDBsum; 4GRB; -.
DR   PDBsum; 4GUB; -.
DR   PDBsum; 4GYW; -.
DR   PDBsum; 4GYY; -.
DR   PDBsum; 4GZ3; -.
DR   PDBsum; 4IB5; -.
DR   PDBsum; 4KWP; -.
DR   PDBsum; 4MD7; -.
DR   PDBsum; 4MD8; -.
DR   PDBsum; 4MD9; -.
DR   PDBsum; 4NH1; -.
DR   PDBsum; 4RLL; -.
DR   PDBsum; 4UB7; -.
DR   PDBsum; 4UBA; -.
DR   PDBsum; 5B0X; -.
DR   PDBsum; 5CLP; -.
DR   PDBsum; 5CQU; -.
DR   PDBsum; 5CQW; -.
DR   PDBsum; 5CS6; -.
DR   PDBsum; 5CSH; -.
DR   PDBsum; 5CSP; -.
DR   PDBsum; 5CSV; -.
DR   PDBsum; 5CT0; -.
DR   PDBsum; 5CTP; -.
DR   PDBsum; 5CU0; -.
DR   PDBsum; 5CU2; -.
DR   PDBsum; 5CU3; -.
DR   PDBsum; 5CU4; -.
DR   PDBsum; 5CU6; -.
DR   PDBsum; 5CVF; -.
DR   PDBsum; 5CVG; -.
DR   PDBsum; 5CVH; -.
DR   PDBsum; 5CX9; -.
DR   PDBsum; 5H8B; -.
DR   PDBsum; 5H8E; -.
DR   PDBsum; 5H8G; -.
DR   PDBsum; 5HGV; -.
DR   PDBsum; 5KU8; -.
DR   PDBsum; 5KWH; -.
DR   PDBsum; 5M44; -.
DR   PDBsum; 5M4C; -.
DR   PDBsum; 5M4F; -.
DR   PDBsum; 5M4I; -.
DR   PDBsum; 5MMF; -.
DR   PDBsum; 5MMR; -.
DR   PDBsum; 5MO5; -.
DR   PDBsum; 5MO6; -.
DR   PDBsum; 5MO7; -.
DR   PDBsum; 5MO8; -.
DR   PDBsum; 5MOD; -.
DR   PDBsum; 5MOE; -.
DR   PDBsum; 5MOH; -.
DR   PDBsum; 5MOT; -.
DR   PDBsum; 5MOV; -.
DR   PDBsum; 5MOW; -.
DR   PDBsum; 5MP8; -.
DR   PDBsum; 5MPJ; -.
DR   PDBsum; 5N1V; -.
DR   PDBsum; 5N9K; -.
DR   PDBsum; 5N9L; -.
DR   PDBsum; 5N9N; -.
DR   PDBsum; 5NQC; -.
DR   PDBsum; 5OMY; -.
DR   PDBsum; 5ONI; -.
DR   PDBsum; 5OQU; -.
DR   PDBsum; 5ORH; -.
DR   PDBsum; 5ORJ; -.
DR   PDBsum; 5ORK; -.
DR   PDBsum; 5OS7; -.
DR   PDBsum; 5OS8; -.
DR   PDBsum; 5OSL; -.
DR   PDBsum; 5OSP; -.
DR   PDBsum; 5OSR; -.
DR   PDBsum; 5OSU; -.
DR   PDBsum; 5OSZ; -.
DR   PDBsum; 5OT5; -.
DR   PDBsum; 5OT6; -.
DR   PDBsum; 5OTD; -.
DR   PDBsum; 5OTH; -.
DR   PDBsum; 5OTI; -.
DR   PDBsum; 5OTL; -.
DR   PDBsum; 5OTO; -.
DR   PDBsum; 5OTP; -.
DR   PDBsum; 5OTQ; -.
DR   PDBsum; 5OTR; -.
DR   PDBsum; 5OTS; -.
DR   PDBsum; 5OTY; -.
DR   PDBsum; 5OTZ; -.
DR   PDBsum; 5OUE; -.
DR   PDBsum; 5OUL; -.
DR   PDBsum; 5OUM; -.
DR   PDBsum; 5OUU; -.
DR   PDBsum; 5OWH; -.
DR   PDBsum; 5OWL; -.
DR   PDBsum; 5OYF; -.
DR   PDBsum; 5T1H; -.
DR   PDBsum; 5VIE; -.
DR   PDBsum; 5VIF; -.
DR   PDBsum; 5ZN0; -.
DR   PDBsum; 5ZN1; -.
DR   PDBsum; 5ZN2; -.
DR   PDBsum; 5ZN3; -.
DR   PDBsum; 5ZN4; -.
DR   PDBsum; 5ZN5; -.
DR   PDBsum; 6A1C; -.
DR   PDBsum; 6E37; -.
DR   PDBsum; 6EHK; -.
DR   PDBsum; 6EHU; -.
DR   PDBsum; 6EII; -.
DR   PDBsum; 6FVF; -.
DR   PDBsum; 6FVG; -.
DR   PDBsum; 6GIH; -.
DR   PDBsum; 6GMD; -.
DR   PDBsum; 6HBN; -.
DR   PDBsum; 6HME; -.
DR   PDBsum; 6HNW; -.
DR   PDBsum; 6HNY; -.
DR   PDBsum; 6HOP; -.
DR   PDBsum; 6HOQ; -.
DR   PDBsum; 6HOR; -.
DR   PDBsum; 6HOT; -.
DR   PDBsum; 6HOU; -.
DR   PDBsum; 6JWA; -.
DR   PDBsum; 6L1Z; -.
DR   PDBsum; 6L21; -.
DR   PDBsum; 6L22; -.
DR   PDBsum; 6L23; -.
DR   PDBsum; 6L24; -.
DR   PDBsum; 6Q38; -.
DR   PDBsum; 6Q4Q; -.
DR   PDBsum; 6QY7; -.
DR   PDBsum; 6RB1; -.
DR   PDBsum; 6RCB; -.
DR   PDBsum; 6RCM; -.
DR   PDBsum; 6RFE; -.
DR   PDBsum; 6RFF; -.
DR   PDBsum; 6SPW; -.
DR   PDBsum; 6SPX; -.
DR   PDBsum; 6TEI; -.
DR   PDBsum; 6TLL; -.
DR   PDBsum; 6TLO; -.
DR   PDBsum; 6TLP; -.
DR   PDBsum; 6TLR; -.
DR   PDBsum; 6TLS; -.
DR   PDBsum; 6TLU; -.
DR   PDBsum; 6TLV; -.
DR   PDBsum; 6TLW; -.
DR   PDBsum; 6YPG; -.
DR   PDBsum; 6YPH; -.
DR   PDBsum; 6YPJ; -.
DR   PDBsum; 6YPK; -.
DR   PDBsum; 6YPN; -.
DR   PDBsum; 6YUL; -.
DR   PDBsum; 6YUM; -.
DR   PDBsum; 6YZH; -.
DR   PDBsum; 6Z19; -.
DR   PDBsum; 6Z83; -.
DR   PDBsum; 6Z84; -.
DR   PDBsum; 7A49; -.
DR   PDBsum; 7A4B; -.
DR   PDBsum; 7A4C; -.
DR   PDBsum; 7AT5; -.
DR   PDBsum; 7AY9; -.
DR   PDBsum; 7AYA; -.
DR   PDBsum; 7B8H; -.
DR   PDBsum; 7B8I; -.
DR   PDBsum; 7BU4; -.
DR   PDBsum; 7L1X; -.
DR   PDBsum; 7PSU; -.
DR   AlphaFoldDB; P68400; -.
DR   SMR; P68400; -.
DR   BioGRID; 107841; 820.
DR   ComplexPortal; CPX-2437; Casein kinase II complex, CSNK2A1-CNSK2A2 variant.
DR   ComplexPortal; CPX-914; Casein kinase II complex, CSNK2A1 variant.
DR   CORUM; P68400; -.
DR   DIP; DIP-32682N; -.
DR   IntAct; P68400; 406.
DR   MINT; P68400; -.
DR   STRING; 9606.ENSP00000217244; -.
DR   BindingDB; P68400; -.
DR   ChEMBL; CHEMBL3629; -.
DR   DrugBank; DB01765; (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid.
DR   DrugBank; DB03035; 1,8-Di-Hydroxy-4-Nitro-Anthraquinone.
DR   DrugBank; DB02170; 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One.
DR   DrugBank; DB08338; 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one.
DR   DrugBank; DB08354; 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE.
DR   DrugBank; DB08360; 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE.
DR   DrugBank; DB08353; 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE.
DR   DrugBank; DB07802; 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE.
DR   DrugBank; DB08345; 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE.
DR   DrugBank; DB03924; 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone.
DR   DrugBank; DB00171; ATP.
DR   DrugBank; DB03127; Benzamidine.
DR   DrugBank; DB08473; Dichlororibofuranosylbenzimidazole.
DR   DrugBank; DB04719; DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE.
DR   DrugBank; DB08846; Ellagic acid.
DR   DrugBank; DB07715; Emodin.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08340; N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE.
DR   DrugBank; DB08362; N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE.
DR   DrugBank; DB04721; N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB08660; Quinalizarin.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB04720; S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE.
DR   DrugBank; DB04462; Tetrabromo-2-Benzotriazole.
DR   DrugCentral; P68400; -.
DR   GuidetoPHARMACOLOGY; 1549; -.
DR   MoonDB; P68400; Predicted.
DR   GlyGen; P68400; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; P68400; -.
DR   MetOSite; P68400; -.
DR   PhosphoSitePlus; P68400; -.
DR   SwissPalm; P68400; -.
DR   BioMuta; CSNK2A1; -.
DR   DMDM; 55977123; -.
DR   EPD; P68400; -.
DR   jPOST; P68400; -.
DR   MassIVE; P68400; -.
DR   MaxQB; P68400; -.
DR   PaxDb; P68400; -.
DR   PeptideAtlas; P68400; -.
DR   PRIDE; P68400; -.
DR   ProteomicsDB; 57536; -. [P68400-1]
DR   ProteomicsDB; 57537; -. [P68400-2]
DR   Antibodypedia; 6236; 756 antibodies from 41 providers.
DR   DNASU; 1457; -.
DR   Ensembl; ENST00000217244.9; ENSP00000217244.3; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000349736.10; ENSP00000339247.6; ENSG00000101266.19. [P68400-2]
DR   Ensembl; ENST00000400217.7; ENSP00000383076.2; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000643660.1; ENSP00000495248.1; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000644003.1; ENSP00000495387.1; ENSG00000101266.19. [P68400-2]
DR   Ensembl; ENST00000645623.1; ENSP00000495998.1; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000646305.1; ENSP00000495902.1; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000646477.1; ENSP00000495439.1; ENSG00000101266.19. [P68400-2]
DR   Ensembl; ENST00000646561.1; ENSP00000496569.1; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000646814.1; ENSP00000495422.1; ENSG00000101266.19. [P68400-1]
DR   Ensembl; ENST00000647348.1; ENSP00000495912.1; ENSG00000101266.19. [P68400-1]
DR   GeneID; 1457; -.
DR   KEGG; hsa:1457; -.
DR   MANE-Select; ENST00000217244.9; ENSP00000217244.3; NM_177559.3; NP_808227.1.
DR   UCSC; uc002wdw.2; human. [P68400-1]
DR   CTD; 1457; -.
DR   DisGeNET; 1457; -.
DR   GeneCards; CSNK2A1; -.
DR   GeneReviews; CSNK2A1; -.
DR   HGNC; HGNC:2457; CSNK2A1.
DR   HPA; ENSG00000101266; Low tissue specificity.
DR   MalaCards; CSNK2A1; -.
DR   MIM; 115440; gene.
DR   MIM; 617062; phenotype.
DR   neXtProt; NX_P68400; -.
DR   OpenTargets; ENSG00000101266; -.
DR   PharmGKB; PA26957; -.
DR   VEuPathDB; HostDB:ENSG00000101266; -.
DR   eggNOG; KOG0668; Eukaryota.
DR   GeneTree; ENSGT00390000004215; -.
DR   HOGENOM; CLU_000288_70_4_1; -.
DR   InParanoid; P68400; -.
DR   OMA; ACEKRPQ; -.
DR   OrthoDB; 1098380at2759; -.
DR   PhylomeDB; P68400; -.
DR   TreeFam; TF300483; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P68400; -.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-201688; WNT mediated activation of DVL.
DR   Reactome; R-HSA-2514853; Condensation of Prometaphase Chromosomes.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6814122; Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding.
DR   Reactome; R-HSA-8934903; Receptor Mediated Mitophagy.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway.
DR   SignaLink; P68400; -.
DR   SIGNOR; P68400; -.
DR   BioGRID-ORCS; 1457; 99 hits in 1087 CRISPR screens.
DR   ChiTaRS; CSNK2A1; human.
DR   EvolutionaryTrace; P68400; -.
DR   GeneWiki; Casein_kinase_2,_alpha_1; -.
DR   GenomeRNAi; 1457; -.
DR   Pharos; P68400; Tchem.
DR   PRO; PR:P68400; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P68400; protein.
DR   Bgee; ENSG00000101266; Expressed in cortical plate and 201 other tissues.
DR   ExpressionAtlas; P68400; baseline and differential.
DR   Genevisible; P68400; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016581; C:NuRD complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0005956; C:protein kinase CK2 complex; IDA:CAFA.
DR   GO; GO:0016580; C:Sin3 complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051879; F:Hsp90 protein binding; TAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0061077; P:chaperone-mediated protein folding; TAS:UniProtKB.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; TAS:ARUK-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IGI:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:CAFA.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:1905818; P:regulation of chromosome separation; IMP:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd14132; STKc_CK2_alpha; 1.
DR   InterPro; IPR045216; CK2_alpha.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24054; PTHR24054; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Biological rhythms; Cell cycle; Disease variant; Intellectual disability;
KW   Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Wnt signaling pathway.
FT   CHAIN           1..391
FT                   /note="Casein kinase II subunit alpha"
FT                   /id="PRO_0000085883"
FT   DOMAIN          39..324
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          36..41
FT                   /note="Interaction with beta subunit"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        156
FT                   /note="Proton acceptor"
FT   BINDING         45..53
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         68
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         344
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:7592773"
FT   MOD_RES         360
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:7592773"
FT   MOD_RES         362
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:7592773"
FT   MOD_RES         370
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:7592773,
FT                   ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         1..136
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041925"
FT   VARIANT         47
FT                   /note="R -> Q (in OCNDS; dbSNP:rs869312845)"
FT                   /evidence="ECO:0000269|PubMed:27048600"
FT                   /id="VAR_077045"
FT   VARIANT         50
FT                   /note="Y -> S (in OCNDS; dbSNP:rs869312849)"
FT                   /evidence="ECO:0000269|PubMed:27048600"
FT                   /id="VAR_077046"
FT   VARIANT         175
FT                   /note="D -> G (in OCNDS; dbSNP:rs869312848)"
FT                   /evidence="ECO:0000269|PubMed:27048600"
FT                   /id="VAR_077047"
FT   VARIANT         198
FT                   /note="K -> R (in OCNDS; dbSNP:rs869312840)"
FT                   /evidence="ECO:0000269|PubMed:27048600"
FT                   /id="VAR_077048"
FT   CONFLICT        128
FT                   /note="L -> F (in Ref. 3; CAA49758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        256
FT                   /note="D -> G (in Ref. 3; CAA49758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        287
FT                   /note="S -> R (in Ref. 3; CAA49758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        351
FT                   /note="M -> V (in Ref. 3; CAA49758)"
FT                   /evidence="ECO:0000305"
FT   STRAND          10..12
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            13..18
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           21..24
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           26..28
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          29..32
FT                   /evidence="ECO:0007829|PDB:6YZH"
FT   HELIX           36..38
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          39..47
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          49..58
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            59..61
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          64..70
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            72..74
FT                   /evidence="ECO:0007829|PDB:5CU6"
FT   HELIX           75..88
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          97..102
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            104..106
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          107..114
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            118..120
FT                   /evidence="ECO:0007829|PDB:5CVG"
FT   HELIX           121..124
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           125..127
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           130..149
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           159..161
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          162..165
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           166..168
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          170..173
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:5ZN2"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           200..203
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           212..227
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          230..233
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           238..249
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           251..261
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           267..269
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            270..272
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           281..284
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   TURN            287..289
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           290..292
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           295..304
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           309..311
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           315..318
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           322..324
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   HELIX           325..331
FT                   /evidence="ECO:0007829|PDB:3WAR"
FT   STRAND          333..335
FT                   /evidence="ECO:0007829|PDB:1JWH"
SQ   SEQUENCE   391 AA;  45144 MW;  D3B6F5D13FF7422D CRC64;
     MSGPVPSRAR VYTDVNTHRP REYWDYESHV VEWGNQDDYQ LVRKLGRGKY SEVFEAINIT
     NNEKVVVKIL KPVKKKKIKR EIKILENLRG GPNIITLADI VKDPVSRTPA LVFEHVNNTD
     FKQLYQTLTD YDIRFYMYEI LKALDYCHSM GIMHRDVKPH NVMIDHEHRK LRLIDWGLAE
     FYHPGQEYNV RVASRYFKGP ELLVDYQMYD YSLDMWSLGC MLASMIFRKE PFFHGHDNYD
     QLVRIAKVLG TEDLYDYIDK YNIELDPRFN DILGRHSRKR WERFVHSENQ HLVSPEALDF
     LDKLLRYDHQ SRLTAREAME HPYFYTVVKD QARMGSSSMP GGSTPVSSAN MMSGISSVPT
     PSPLGPLAGS PVIAAANPLG MPVPAAAGAQ Q
//
